Document Detail

MRP14 is elevated in the bronchoalveolar lavage fluid of fibrosing interstitial lung diseases.
MedLine Citation:
PMID:  20550547     Owner:  NLM     Status:  MEDLINE    
Pulmonary fibrosis is defined by an overgrowth of fibroblasts and extracellular matrix deposition, and results in respiratory dysfunction that is often fatal. It is the end stage in many chronic inflammatory interstitial lung diseases (ILD) such as sarcoidosis and idiopathic pulmonary fibrosis (IPF). The myeloid-related proteins (MRPs) belong to the S100 family of calcium-binding proteins and are highly expressed by neutrophils, macrophages and epithelial cells during chronic inflammation. MRP14 stimulates fibroblast proliferation in vitro and is expressed in granulomas from sarcoidosis patients. We hypothesized that MRP14 may be a biomarker for fibrotic interstitial lung diseases. The objective of this study was to investigate whether levels of MRP14 in the bronchoalveolar lavage fluid (BALF) of patients with sarcoidosis and IPF correlate with clinical parameters. We used an enzyme-linked immunosorbent assay (ELISA) to measure MRP14 in BALF of 74 sarcoidosis patients, 54 IPF patients and 19 controls. Mean BALF levels of MRP14 were elevated significantly in IPF (P < 0.001) and sarcoidosis (P < 0.05) patients compared to controls. MRP14 levels were associated linearly with sarcoidosis disease severity based on chest radiographic stage. Moreover, BALF MRP14 levels were correlated inversely with diffusion capacity and forced vital capacity in sarcoidosis patients. In IPF patients, a correlation with BALF neutrophil percentage was found. In conclusion, BALF MRP14 levels are elevated in IPF and sarcoidosis and are associated with disease severity in sarcoidosis. The results support the need for further studies into the role of MRP14 in the pathogenesis of lung fibrosis.
N M Korthagen; M M Nagtegaal; C H M van Moorsel; K M Kazemier; J M M van den Bosch; J C Grutters
Related Documents :
8893387 - Nephrolithiasis as a presenting feature of chronic sarcoidosis: a prospective study.
1729817 - Diagnosis of pericardial abnormalities by 2d-echo: a pathology-echocardiography correla...
11888967 - Clinical significance of pleural effusion in acute aortic dissection.
6633367 - Pleuroperitoneal effusion without ascites.
9476847 - Small airways function in patients with inflammatory bowel disease.
6642037 - Effect of photochemotherapy on the cardiovascular system.
Publication Detail:
Type:  Journal Article     Date:  2010-06-09
Journal Detail:
Title:  Clinical and experimental immunology     Volume:  161     ISSN:  1365-2249     ISO Abbreviation:  Clin. Exp. Immunol.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-26     Completed Date:  2010-08-27     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  0057202     Medline TA:  Clin Exp Immunol     Country:  England    
Other Details:
Languages:  eng     Pagination:  342-7     Citation Subset:  IM    
Center for Interstitial Lung Diseases, Department of Pulmonology, St Antonius Hospital Nieuwegein, the Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Markers / analysis,  metabolism
Bronchoalveolar Lavage Fluid / chemistry*,  cytology
Calgranulin B / analysis,  metabolism*
Carbon Monoxide / metabolism
Cell Count
Forced Expiratory Volume / physiology
Idiopathic Pulmonary Fibrosis / metabolism,  pathology,  physiopathology
Lung Diseases, Interstitial / complications,  metabolism*
Middle Aged
Neutrophils / pathology
Pulmonary Diffusing Capacity / physiology
Pulmonary Fibrosis / etiology,  metabolism*
Sarcoidosis, Pulmonary / diagnosis,  metabolism,  physiopathology
Vital Capacity / physiology
Young Adult
Reg. No./Substance:
0/Biological Markers; 0/Calgranulin B; 630-08-0/Carbon Monoxide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of an immunotoxin to folate receptor beta on bleomycin-induced experimental pulmonary fibrosi...
Next Document:  Association of NKG2A with treatment for chronic hepatitis C virus infection.